While talks of a rumored swap between Merck's consumer-goods business and Novartis' animal health and vaccines units have cooled, sources now tell The Wall Street Journal they expect industry heavyweights to put in bids that could surpass $10 billion, and Merck has already received preliminary offers for the business.
Any industry that's undergoing as much change as biopharma is always looking for leadership. Old marketing practices are being blown apart, R&D is being subjected to emergency surgery, drug...
For nearly 100 years, Merck and Merck KGaA have been independent entities, but their shared name has led to confusion, sniping and even legal fracas. Now the two former relatives are working behind closed doors to smooth things over, Bloomberg reports, but don't expect either to bend much on the issue of identity.
Sanofi and its top-selling Lantus may have bought some time last month with a legal wrench in Eli Lilly's spokes, but now Merck has bulldozed its way into the conversation with plans to kick off late-stage studies for its own knockoff of the blockbuster drug, further complicating an already heated fight.
The President's Cancer Panel is urging federal and state health authorities to do a better job protecting children from preventable cancers by improving access to the HPV vaccine, which could mean a big bump in sales.
The risks of women developing a blood clot while using certain contraceptives are well known and have spawned thousands of lawsuits and resulted in billions of dollars in payments. Now it is Merck's turn to pony up, with a $100 million settlement that some say lets it off cheap.
Last week Novartis' vaccine unit posted yet another operating loss, extending its streak in the red to four years. Yet despite its well-known, long-term problems, suitors are reportedly circling the unit, with the potential of Bexsero and Menveo likely to be a factor attracting potential buyers.
Merck's sales continue to get whacked by the loss of patent protection for its asthma blockbuster Singulair, but it managed to pull out fourth-quarter earnings that only barely missed Wall Street expectations, avoiding the "mega-miss" some analysts were braced for.
One in three people in the U.S. either already have or are at high risk of developing diabetes, and analyzing genetic data for answers about how best to treat these patients is a daunting task. Now a collection of Big Pharma companies are teaming up to share the burden.
A couple of weeks back, the Street was abuzz that Merck would hand over its consumer-health business for Novartis' animal-health and vaccines units. Yesterday, word was that Merck has some consumer-goods giants shopping its consumer-health aisle.